Antidiabetic Drugs — All Classes

• Pancreatic beta cell dysfunction and impaired insulin secretion: In T2DM, the pancreatic beta cells progressively lose their capacity to sense glucose and secrete appropriate amounts of insulin in response to hyperglycemia—a process called "glucose sensing impairment." This involves defective ATP-sensitive potassium (KATP) channel closure, reduced calcium influx, and impaired exocytosis of insulin granules. Additionally, beta cell apoptosis occurs due to glucotoxicity (chronic hyperglycemia-induced cellular stress) and lipotoxicity (free fatty acid-induced mitochondrial dysfunction and endoplasmic reticulum stress). The incretin axis, which normally accounts for 50-70% of the postprandial insulin secretion via glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) signaling, becomes progressively impaired (incretin deficiency) through both reduced incretin secretion and accelerated incretin degradation by dipeptidyl peptidase-4 (DPP-4). Amyloid accumulation within beta cells (from misfolding of islet amyloid polypeptide, IAPP) further contributes to beta cell loss.

• Insulin resistance in peripheral tissues: Insulin resistance—defined as reduced biological response to a given concentration of insulin—occurs predominantly in skeletal muscle, adipose tissue, and liver. At the molecular level, this involves reduced insulin receptor tyrosine kinase activity, impaired phosphorylation of insulin receptor substrate proteins (IRS-1, IRS-2), and decreased activation of the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling cascade. In skeletal muscle, this translates to reduced glucose transporter 4 (GLUT4) translocation to the cell membrane, limiting glucose uptake and utilization. Hepatic insulin resistance results in failure of insulin to suppress endogenous glucose production (hepatic gluconeogenesis and glycogenolysis), which remains inappropriately elevated despite hyperglycemia. Adipose tissue insulin resistance leads to increased lipolysis, elevated circulating free fatty acids, and lipid accumulation (hepatic steatosis), perpetuating hepatic and muscle insulin resistance through lipotoxic mechanisms. The precise etiology of insulin resistance involves complex interactions among mitochondrial dysfunction, endoplasmic reticulum stress, chronic low-grade inflammation (elevated TNF-α, IL-6, CRP), and impaired adipokine signaling (reduced adiponectin, excess resistin).

• Increased hepatic glucose production and fasting hyperglycemia: Normally, insulin suppresses gluconeogenesis and glycogenolysis via inhibition of glycogen phosphorylase and phosphofructokinase-2, while activating glycogen synthase. In T2DM, hepatic insulin resistance allows unopposed gluconeogenesis even in the fasted state, contributing 85-90% of endogenous glucose production. The increased flux through gluconeogenic substrates (lactate, amino acids, glycerol) driven by lipolysis perpetuates fasting hyperglycemia. Hepatic glucose output becomes insensitive to both elevated glucose and insulin concentrations, necessitating therapies that directly target hepatic glucose production (metformin, thiazolidinediones, GLP-1 agonists).

• Dysregulation of glucagon secretion: In healthy individuals, high glucose concentrations suppress alpha cell secretion of glucagon through both direct glucose sensing and paracrine signaling from beta cells. In T2DM, this suppression is blunted, resulting in inappropriate glucagon levels despite hyperglycemia. Elevated glucagon stimulates hepatic glucose production through G-protein coupled receptor signaling, increasing cAMP and activation of protein kinase A (PKA), which phosphorylates phosphofructokinase-2 and increases gluconeogenesis. Glucagon antagonism or suppression of glucagon secretion (via GLP-1 agonists) thus offers therapeutic benefit.

• Renal glucose reabsorption and the SGLT2 pathway: The kidneys filter approximately 180 g of glucose daily at the glomerulus; normally >99% is reabsorbed via sodium-glucose cotransporters in the proximal tubule. SGLT2 (sodium-glucose linked transporter 2), located in the S1 and S2 segments of the proximal tubule, mediates ~90% of glucose reabsorption through secondary active transport coupled to sodium reabsorption. In diabetes, increased glomerular filtration of glucose and upregulation of SGLT2 expression contribute to hyperglycemia. Pharmacological SGLT2 inhibition allows glucosuria, reducing the filtered load that is reabsorbed and enabling renal glucose "wasting" as a glycemic control mechanism. This pathway is independent of insulin and beta cell function, making it effective across the spectrum of diabetes severity.

• Gastrointestinal glucose absorption and postprandial hyperglycemia: Alpha-glucosidase enzymes in the small intestinal brush border (maltase, isomaltase, sucrase) and pancreatic amylase hydrolyze complex carbohydrates and disaccharides into monosaccharides for absorption. Rapid glucose absorption contributes to postprandial hyperglycemia, which drives HbA1c elevation and postprandial oxidative stress. Alpha-glucosidase inhibitors slow this enzymatic hydrolysis, flattening the postprandial glucose curve.

• Type 2 diabetes mellitus with insulin resistance as predominant defect: Patients with marked fasting hyperglycemia, elevated hepatic glucose output, and normal or elevated insulin levels benefit from agents addressing hepatic glucose production (metformin, thiazolidinediones) or peripheral insulin sensitivity. Metformin is considered first-line in nearly all patients with T2DM lacking contraindications, as it addresses both hepatic and muscle insulin resistance while providing modest weight loss and cardiovascular protection.

• Type 2 diabetes with progressive beta cell failure: As beta cell function declines over time (HbA1c progressively rising despite therapeutic interventions), agents that stimulate insulin secretion (sulfonylureas, meglitinides, DPP-4 inhibitors, GLP-1 agonists) become necessary. GLP-1 agonists and DPP-4 inhibitors preserve beta cell function through glucose-dependent mechanisms, whereas sulfonylureas provide short-term glycemic control at the cost of accelerated beta cell exhaustion and hypoglycemia risk.

• Type 1 diabetes mellitus: While still primarily managed with insulin therapy, adjunctive agents such as GLP-1 agonists (for weight management and cardiovascular protection) and SGLT2 inhibitors (for renal and cardiovascular benefits, with careful DKA monitoring) are increasingly employed in selected patients.

• Cardiovascular risk reduction and heart failure prevention: SGLT2 inhibitors (empagliflozin, canagliflozin) and GLP-1 agonists (particularly semaglutide, dulaglutide) have demonstrated reduction in major adverse cardiovascular events (MACE), cardiovascular death, and heart failure hospitalization. These agents should be prioritized in patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure with reduced ejection fraction (HFrEF), or high cardiovascular risk, irrespective of baseline HbA1c.

• Chronic kidney disease (CKD) and albuminuria: SGLT2 inhibitors and GLP-1 agonists both slow progression of albuminuria and decline in glomerular filtration rate. SGLT2 inhibitors are particularly valuable in advanced CKD (eGFR 20-45 mL/min/1.73m²) where many glucose-lowering agents become contraindicated, and in both diabetic and non-diabetic CKD.

• Obesity and weight management: GLP-1 agonists (particularly semaglutide at higher doses) and SGLT2 inhibitors produce meaningful weight loss (3-5 kg and 2-4 kg, respectively) through distinct mechanisms. GLP-1 agonists reduce appetite via central nervous system GLP-1 receptor signaling and slow gastric emptying; SGLT2 inhibitors increase osmotic diuresis and reduce caloric reabsorption. These agents are preferred in obese patients and those with metabolic syndrome.

• Acute coronary syndrome or recent myocardial infarction: Early initiation of cardioprotective agents (SGLT2 inhibitors, GLP-1 agonists) is recommended to reduce recurrent events and mortality, with these therapies superseding traditional glycemic targets in acute presentations.

• Hyperlipidemia and metabolic syndrome: Thiazolidinediones improve lipid profiles (increased HDL, reduced triglycerides) and insulin sensitivity despite weight gain; GLP-1 agonists reduce triglycerides and LDL cholesterol while promoting weight loss.

• Sulfonylurea-induced hypoglycemia and secondary failure: Patients experiencing recurrent hypoglycemia on sulfonylureas should be transitioned to agents with lower hypoglycemia risk (metformin, SGLT2 inhibitors, GLP-1 agonists, DPP-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors).

• Hyperglycemic symptoms prompting antidiabetic initiation: Polyuria (osmotic diuresis from glucose filtration), polydipsia (osmotic dehydration and thirst center activation), polyphagia (hormonal dysregulation reducing satiety), fatigue (impaired energy metabolism and glycation-induced cellular dysfunction), and blurred vision (osmotic lens swelling). These symptoms typically emerge when fasting glucose exceeds 200 mg/dL or random glucose >250 mg/dL; patients with slowly developing hyperglycemia may be asymptomatic despite elevated HbA1c.

• Postprandial hyperglycemia manifestations: Transient visual disturbances, postprandial fatigue or "brain fog," reactive hypoglycemia if insulin secretion is exaggerated. Postprandial hyperglycemia (glucose >180 mg/dL at 2 hours post-meal) drives more HbA1c elevation than fasting hyperglycemia in early diabetes and is the primary target of alpha-glucosidase inhibitors.

• Symptomatic hypoglycemia from glucose-lowering agents: Tremulousness, palpitations, anxiety, diaphoresis, hunger (adrenergic symptoms via catecholamine release in response to acute hypoglycemia), progressing to confusion, altered behavior, seizures, and loss of consciousness (neuroglycopenic symptoms from brain glucose deprivation). Sulfonylureas carry highest hypoglycemia risk; meglitinides have intermediate risk; insulin and GLP-1 agonists can cause hypoglycemia in combination; metformin, SGLT2 inhibitors, DPP-4 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors rarely cause hypoglycemia as monotherapy.

• Gastrointestinal side effects: GLP-1 agonists commonly cause nausea, vomiting, and diarrhea (40-50% of patients in early therapy) via central GLP-1 receptor stimulation and delayed gastric emptying; alpha-glucosidase inhibitors cause flatulence, bloating, and diarrhea from undigested carbohydrate reaching the colon and bacterial fermentation; metformin causes diarrhea and abdominal discomfort in 20-30% of patients from altered gut microbiota and osmotic effects.

• Weight changes: GLP-1 agonists and SGLT2 inhibitors cause weight loss (3-5 kg and 2-4 kg mean, respectively); thiazolidinediones cause weight gain (2-3 kg), necessitating careful patient counseling and metabolic monitoring. Sulfonylureas and meglitinides also promote modest weight gain (1-2 kg) from improved glycemic control allowing more caloric retention.

• Fluid retention and edema: Thiazolidinediones activate peroxisome proliferator-activated receptor gamma (PPAR-γ) in vascular endothelium and adipose tissue, increasing vascular permeability and sodium/fluid reabsorption in renal collecting ducts, resulting in peripheral edema (10-15% of patients) and exacerbation of heart failure. SGLT2 inhibitors cause volume depletion initially (osmotic diuresis), potentially triggering orthostatic hypotension or syncope, particularly in elderly patients or those on concurrent diuretics.

• Genital mycotic infections: SGLT2 inhibitors, by promoting glucosuria, create a glucose-rich urinary environment favoring Candida proliferation, resulting in genital itching, erythema, discharge, and dysuria in 5-15% of patients (higher in women). Adequate hydration and perineal hygiene reduce incidence.

• Thiazolidinedione-specific effects: Fluid retention, weight gain, and exacerbation of heart failure (contraindicate in NYHA class III-IV); increased risk of fractures, particularly in postmenopausal women, from impaired osteoblast differentiation and increased bone resorption. Rosiglitazone carries cardiovascular risk (myocardial ischemia) and is rarely used; pioglitazone may lower bladder cancer risk slightly.

• Pancreatitis from incretin-based agents: Rare but documented association with GLP-1 agonists and DPP-4 inhibitors (~0.1-0.2% incidence); presents with severe epigastric pain, elevated lipase, and amylase. Mechanistically, incretin agents may trigger excessive beta cell and acinar cell degranulation or promote mast cell trophism within pancreatic tissue.

• Diabetic ketoacidosis (DKA) in SGLT2 inhibitor use: "Euglycemic DKA" with glucose <250 mg/dL has been reported with SGLT2 inhibitors, particularly in T1DM or during periods of reduced carbohydrate intake, intense exercise, or illness. The mechanism involves reduction of renal glucose clearance (allowing continued insulin suppression of hepatic ketogenesis) despite lower plasma glucose, leading to unopposed ketone production. Present with normal or only mildly elevated glucose but significant metabolic acidosis (pH <7.3) and elevated beta-hydroxybutyrate.

• Acute kidney injury and volume depletion: SGLT2 inhibitors and GLP-1 agonists can precipitate acute kidney injury in susceptible populations (elderly, dehydrated, on ACE inhibitors/ARBs) through osmotic diuresis and prerenal azotemia. Adequate hydration counseling is essential.

• Assessment of glycemic control and HbA1c measurement: HbA1c reflects average plasma glucose over 8-12 weeks via non-enzymatic glycation of hemoglobin; it is the standard marker of glycemic control and target for diabetes management. HbA1c

Biguanides (metformin)

• Lactic acidosis: metformin inhibits mitochondrial complex I and hepatic gluconeogenesis from lactate; accumulation in renal failure allows lactate to build. Per ADA Standards of Care and FDA labeling, avoid initiation at eGFR <45 and discontinue at eGFR <30; hold around iodinated contrast, sepsis, hypoxia, and decompensated heart failure. Treatment is supportive with hemodialysis (removes drug and corrects acidosis) — there is no pharmacologic antidote.
• Vitamin B12 malabsorption: calcium-dependent ileal uptake of the B12–intrinsic factor complex is impaired; ADA advises periodic B12 measurement, especially with anemia or peripheral neuropathy.

Insulin secretagogues

• Sulfonylureas/meglitinides: KATP channel closure is glucose-*independent*, so hypoglycemia occurs even when fasting. Glyburide is the highest-risk agent in the elderly and CKD (active renal-cleared metabolites) and appears on the AGS Beers Criteria. Treat with oral carbohydrate or IV dextrose; glucagon 1 mg IM if no access. For refractory or recurrent sulfonylurea hypoglycemia, octreotide suppresses the rebound insulin release provoked by dextrose.
• First-generation agents (chlorpropamide): disulfiram-like reaction and SIADH.

Other classes

• Thiazolidinediones: PPAR-γ–mediated distal nephron sodium retention causes edema and heart-failure decompensation — contraindicated in NYHA class III–IV; also distal limb fractures in women and elevated ALT monitoring (legacy of troglitazone hepatotoxicity).
• GLP-1 receptor agonists: contraindicated with personal/family history of medullary thyroid carcinoma or MEN2 (rodent C-cell hyperplasia; boxed warning); pancreatitis, cholelithiasis, delayed gastric emptying (aspiration risk at anesthesia induction), retinopathy progression with rapid A1c fall.
• DPP-4 inhibitors: angioedema/urticaria (additive with ACE inhibitors, as both raise substance P/bradykinin), arthralgia; saxagliptin and alogliptin increased heart-failure hospitalization.
• SGLT2 inhibitors: euglycemic ketoacidosis, genital mycotic infection, rare Fournier gangrene, volume depletion/AKI; FDA labeling advises holding several days before elective surgery.
• Insulin: hypoglycemia, weight gain, lipohypertrophy at repeated sites, and intracellular potassium shift.
• Alpha-glucosidase inhibitors: flatulence, dose-related transaminitis.

• Metformin does not cause hypoglycemia: it lowers hepatic glucose output rather than stimulating insulin release, so a stem describing a patient on monotherapy with documented hypoglycemia points to a secretagogue, insulin, or surreptitious use — not metformin. It remains ADA-endorsed first-line for most T2DM.
• Comorbidity trumps HbA1c: the ADA Standards of Care direct that a patient with HFrEF, CKD with albuminuria, or established ASCVD receive an SGLT2 inhibitor (heart failure/CKD) or a GLP-1 receptor agonist (ASCVD, obesity) regardless of whether HbA1c is at goal. KDIGO makes the same call for diabetic kidney disease. The common distractor is adding a sulfonylurea or a DPP-4 inhibitor — cheap and effective glycemically, but no cardiovascular or renal outcome benefit.
• Normal glucose does not exclude DKA on an SGLT2 inhibitor: euglycemic DKA presents with anion-gap acidosis and glucose often <250 mg/dL. Best next step is beta-hydroxybutyrate and a venous blood gas, not repeating the fingerstick.
• Medullary thyroid carcinoma / MEN2 is the GLP-1 contraindication examiners test, derived from rodent C-cell tumors — an exam-favorite "which drug must you avoid" pairing.
• Sulfonylurea overdose refractory to dextrose → octreotide: dextrose alone provokes further insulin secretion and recurrent hypoglycemia. Long-acting glyburide in an elderly patient with CKD is the classic setup.
• Acarbose-associated hypoglycemia must be treated with glucose (dextrose), not sucrose or a candy bar, because brush-border disaccharidase inhibition blocks sucrose cleavage.
• Distinguish the two "edema" drugs: thiazolidinediones retain fluid and worsen heart failure; SGLT2 inhibitors do the opposite and are guideline-directed HFrEF therapy per ACC/AHA.
• Metformin plus contrast or acute illness: hold the drug — lactic acidosis risk rises with any hypoperfusion state.